Daewoong Pharma signs USD 5 mn botulinum toxin supply agreement with Egypt

South Korea’s Daewoong Pharma signed a five-year, USD 5 mn agreement with the Egyptian International Medical Services to distribute its self-developed Botox product in Egypt, which is the region’s second-largest Botox market, The Investors reports. The Korean company’s product, Nabota, has yet to receive market authorization in Egypt.